Fresenius Medical Care (NYSE: FMS) and Caladrius Biosciences (NASDAQ:CLBS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, profitability, institutional ownership and earnings.
This is a summary of recent recommendations and price targets for Fresenius Medical Care and Caladrius Biosciences, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Fresenius Medical Care||0||3||4||0||2.57|
Fresenius Medical Care currently has a consensus price target of $53.00, indicating a potential upside of 5.12%. Caladrius Biosciences has a consensus price target of $9.50, indicating a potential upside of 135.15%. Given Caladrius Biosciences’ stronger consensus rating and higher possible upside, analysts clearly believe Caladrius Biosciences is more favorable than Fresenius Medical Care.
Volatility & Risk
Fresenius Medical Care has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500. Comparatively, Caladrius Biosciences has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500.
Fresenius Medical Care pays an annual dividend of $0.44 per share and has a dividend yield of 0.9%. Caladrius Biosciences does not pay a dividend. Fresenius Medical Care pays out 19.9% of its earnings in the form of a dividend. Fresenius Medical Care has raised its dividend for 2 consecutive years.
Insider and Institutional Ownership
2.5% of Fresenius Medical Care shares are owned by institutional investors. Comparatively, 7.8% of Caladrius Biosciences shares are owned by institutional investors. 7.5% of Caladrius Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This table compares Fresenius Medical Care and Caladrius Biosciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Fresenius Medical Care||7.29%||11.09%||4.92%|
Valuation & Earnings
This table compares Fresenius Medical Care and Caladrius Biosciences’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Fresenius Medical Care||$20.09 billion||1.54||$1.45 billion||$2.21||22.81|
|Caladrius Biosciences||$35.28 million||1.10||$22.97 million||($1.78)||-2.27|
Fresenius Medical Care has higher revenue and earnings than Caladrius Biosciences. Caladrius Biosciences is trading at a lower price-to-earnings ratio than Fresenius Medical Care, indicating that it is currently the more affordable of the two stocks.
Fresenius Medical Care beats Caladrius Biosciences on 11 of the 17 factors compared between the two stocks.
Fresenius Medical Care Company Profile
Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the U.S. for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems for the treatment of ESRD; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, hospitalist and intensivist, medical cost management, ambulatory surgery center, health plan, urgent care, physician nephrology and cardiology, and ambulant treatment services. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; and offers non-dialysis products, including acute cardiopulmonary and apheresis products. The company sells its products to clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2017, it operated 3,752 outpatient dialysis clinics in approximately 50 countries. The company has operations in Germany, the United States, and internationally. Fresenius Medical Care AG & Co. KGaA was founded in 1996 and is headquartered in Bad Homburg, Germany.
Caladrius Biosciences Company Profile
Caladrius Biosciences, Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company is focused on commencing The Sanford Project: T-Rex Study, a Phase II prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate its Treg product candidate, CLBS03, in adolescents with recent onset T1D. The Company plans to develop its product candidate, CLBS12, in Japan, which is an autologous therapy that derives its cells from peripheral blood through apheresis.
Receive News & Ratings for Fresenius Medical Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care and related companies with MarketBeat.com's FREE daily email newsletter.